ADMA Biologics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2023 Annual Meeting of Stockholders held by ADMA Biologics, Inc. on June 6, 2023. The filing details the voting outcomes for director elections and the ratification of the independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes and Voting Results
At the Annual Meeting, 179,474,264 shares were represented, constituting a quorum out of 222,249,295 shares outstanding as of the April 10, 2023 record date. The following matters were approved:
- Election of Director: Bryant E. Fong was elected as a Class I director to serve until the 2026 Annual Meeting. He received 104,032,764 votes "For," 43,796,163 votes "Withheld," and there were 31,645,337 Broker Non-Votes.
- Ratification of Auditors: The appointment of CohnReznick LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023, was ratified. The vote was 178,835,482 "For," 407,959 "Against," and 230,823 "Abstain."
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the procedural results of the stockholder vote.
Key Facts for Investor Verification
- Verify the tenure of the newly elected Class I director, Bryant E. Fong, which extends to the 2026 Annual Meeting.
- Confirm the engagement of CohnReznick LLP as the independent auditor for the fiscal year ending December 31, 2023.
- Note the significant number of Broker Non-Votes (31,645,337) regarding the director election, which may indicate institutional holdings where brokers lacked discretionary voting power.
- Review the company's most recent 10-K or 10-Q filings for financial performance data, as this 8-K contains no financial metrics.